Compare Enveric Biosciences Inc (ENVB) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Ryanair Holdings plc — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Ryanair Holdings plc trades at $59.4 (market cap $29.86B). The key difference: Ryanair Holdings plc is far larger — about 4816.1× Enveric Biosciences Inc's market cap, and Ryanair Holdings plc pays a 1.51% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | RYAAY | |
|---|---|---|
Market Cap | $6.20M | $29.86B |
Sector | Health | Industrials |
52-Week High | $17.40 | $73.82 |
52-Week Low | $1.27 | $53.24 |
Enterprise Value | $1.30M | $26.83B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
RYAAY trades at $60.19, down 0.59% on the day, with a neutral technical signal and bearish moving averages. The company reported mixed quarterly earnings, missing in Q4 2025 and Q2 2026 but beating in Q1 2026. Fundamentals show strong profitability with a 12.13% net margin and 22.41% ROE, supported by $13.95B revenue in 2025. Analyst sentiment is positive with a 62.5% buy rating, though recent news highlights pressure from lower fares and higher fuel costs.
The outlook for RYAAY is cautiously optimistic, with potential upside from industry consolidation and a strong balance sheet, but near-term risks include volatile fuel prices, competitive pricing pressure, and geopolitical tensions affecting travel demand. The stock's valuation at a P/E of 14.56 appears reasonable if earnings stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
